信达生物的合作伙伴奥霖生物（Ollin Biosciences）近日宣布，其B轮融资已获得超额认购，成功筹集3.3亿美元。这笔资金将专项用于推进其核心候选药物Ibi324（亦称为Oln324）在糖尿病性黄斑水肿（DME）和湿性年龄相关性黄斑变性（湿性AMD）适应症上的全球III期临床开发。根据规划，相关的临床研究预计将于2026年下半年正式启动。
此次融资的顺利完成，凸显了市场对奥霖生物研发管线及其在眼科治疗领域潜力的高度认可。充足的资金将有力支持该药物在全球范围内的关键性临床试验，加速其开发进程，为全球患者带来新的治疗希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.